EL DORADO HILLS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NutraCea announced today that their SynBiotics-3, a proprietary formulation of pre and probiotics, has been approved to be added to the formulary at Mercy Hospital of Folsom as adjunctive therapy in the management of recurrent Clostridia difficile colitis, more commonly known as antibiotic-associated diarrhea.
SynBiotics-3 contains bacteria called Saccharomyces, which have been shown in independent clinical trials to reduce the recurrence rate of C. difficile colitis. In addition, SynBiotics-3 contains NutraCea’s proprietary fructo-oligosaccharide-rich stabilized rice bran derivative “RiSolubles(R)” as well as other “friendly” bacterial strains. Fructo-oligosaccharides (FOS), as prebiotics, have been shown to help support and maintain healthy intestinal flora.
Dr. Eliot Drell and Dr. Erick Pecha are board certified gastroenterologists who co-developed the product with Patricia McPeak, Founder of NutraCea. Dr. Drell stated, “We are very gratified that Mercy Hospital of Folsom has agreed to add SynBiotics-3 to their armamentarium for the management of a very challenging and common problem that often accompanies the use of broad-spectrum antibiotic therapy.”
Mercy Hospital of Folsom is part of Catholic Hospitals West, a large organization of Hospitals under the Mercy name, with locations throughout California. The approval is hoped to lead to adoption into formularies throughout this organization as well as other hospitals throughout the country. This will help pave the way for physicians in a hospital setting to begin to prescribe SynBiotics-3 to assist in the management of this condition. SynBiotics-3 has been restricted for use in only those patients who are not immuno-compromised and who can take oral medications.
“This is an historic moment for NutraCea(R) and CHW’s Mercy Hospital of Folsom and constitutes a significant milestone in the implementation of a truly integrative healthcare system, which will allow physicians the opportunity to prescribe natural and effective therapies alongside more conventional treatment modalities for the betterment of their patients. In-patients will now have the same opportunity to benefit from the same probiotics that physicians are recommending to their out-patients,” said Patricia McPeak, Founder and CEO of NutraCea.
About Clostridia difficile colitis
C. difficile colitis can be a serious problem and is most commonly seen as a complication from the use of broad-spectrum antibiotics. These widely used medications suppress a patient’s normal, healthy intestinal flora allowing the C. difficile organism to proliferate. The most common treatment has been the use of other, different antibiotics to eradicate the organism, however, there is always an underlying recurrence rate following standard treatment and recently some resistant species have begun to emerge, hampering physicians’ usual treatment protocols. Although antibiotic-induced diarrhea can be as mild as a self-limited diarrheal disorder, in older debilitated patients, the condition can sometimes be serious requiring hospitalization and intensive treatment. Though rare, the disease can be fatal.
About NutraCea
NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea’s proprietary technology enables the creation of food and nutrition products from rice bran, normally a waste by- product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health-promoting “nutraceuticals,” including natural arthritic relief and cholesterol-lowering products, and all-natural “cosmeceutical” beauty aids. More information can be found in the company’s filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.
Forward Looking Statements
This release contains forward-looking statements, including statements regarding anticipated revenue. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, agreement on the terms of the contemplated agreement with the Dominican Republic government, successful completion of the production facility, product demand and market acceptance, the impact of the competitive products and pricing, new product development, reliance on key strategic alliances, availability of materials, the regulatory environment, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The Company does not undertake to update forward- looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission, including the company’s most recent periodic report.
Company Contact: Margie Adelman Senior V.P. NutraCea 916-933-7000 Ext. 646 916-220-3500 cell Investor Relations Contact: Stephen D. Axelrod, CFA Wolfe Axelrod Weinberger Associates, LLC 212-370-4500
NutraCea
CONTACT: Margie Adelman, Senior V.P., NutraCea, +1-916-933-7000 Ext. 646,+1-916-220-3500 cell; Investor Relations: Stephen D. Axelrod, CFA, WolfeAxelrod Weinberger Associates, LLC, +1-212-370-4500
Web site: http://www.NutraCea.com/
